Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma

Erdafitinib received accelerated approval on April 12, 2019, for patients with metastatic or locally advanced urothelial carcinoma with susceptible fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations and who have progressed during or following at least one platinum-based chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayegh, Nicolas, Tripathi, Nishita, Agarwal, Neeraj, Swami, Umang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522481/
https://www.ncbi.nlm.nih.gov/pubmed/36186154
http://dx.doi.org/10.2147/OTT.S318332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522481/
https://www.ncbi.nlm.nih.gov/pubmed/36186154
http://dx.doi.org/10.2147/OTT.S318332

Ejemplares similares